MD HB395

Beginning July 1, 2025, State funds may not be used to purchase opioid overdose reversal drugs from any entity that was party to a settlement with any state over its role in manufacturing, selling, or distributing prescription opioids

Exempts entities that agreed to provide opioid overdose reversal drugs as part of a settlement executed on or before September 1, 2024, until those settlement terms are fulfilled

Exempts entities with existing state contracts to provide these drugs executed on or before June 30, 2025, until contract terms are fulfilled

Existing state contracts for opioid overdose reversal drugs may not be renewed on or after July 1, 2025

Existing contract obligations and rights are protected from impairment by this Act